Physician profile
John Miller
NPI 1144239096
$5,083.01
in general payments reported to CMS, 2019-2025
37 companies · $1,023 in 2025
The $1,023 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $844 · 2022: $1,193 · 2023: $1,063 · 2024: $960 · 2025: $1,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,045.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,431.66 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $980.25 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $274.40 | 2021-2024 | Repatha, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $259.70 | 2023-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $146.48 | 2021-2024 | Trintellix |
| Abiomed | $121.09 | 2025 | |
| Esperion Therapeutics, INC. | $118.60 | 2021 | |
| Corcept Therapeutics | $108.75 | 2024-2025 | Korlym |
| Axsome Therapeutics, INC. | $105.91 | 2024-2025 | Auvelity |
| Merck Sharp & Dohme LLC | $104.39 | 2022-2023 | Verquvo, Belsomra, Steglujan |
| Otsuka America Pharmaceutical, INC. | $101.35 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $101.29 | 2021-2025 | |
| Exact Sciences Corporation | $95.97 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $87.34 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $83.86 | 2021-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.